CADEMPINO, Switzerland–(BUSINESS WIRE)–#ClinicalTrial—Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientificallyCADEMPINO, Switzerland–(BUSINESS WIRE)–#ClinicalTrial—Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease

CADEMPINO, Switzerland–(BUSINESS WIRE)–#ClinicalTrial—Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial.

IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levodopa therapeutic effect for a longer period of time compared to IR LD/CD. Last year, Zambon Biotech entered into an exclusive licensing agreement with Amneal Pharmaceuticals for IPX203 in the European Union, United Kingdom, and Switzerland. Zambon submitted IPX203 to the EMA for regulatory approval in June 2025.

Dosing the first person in our phase 3b ADIP study marks an important milestone for our company and for the people living with Parkinson’s disease who urgently need new therapies that truly improve their quality of life and the therapeutic outcomes” explained Mathias Knecht, M.D., Chief Medical Officer, Zambon Biotech.We recognise the substantial need for new treatment options, and with ADIP we aim to demonstrate the potential of IPX203 to become a core therapy for people with PD and moderate to severe motor fluctuations”.

ADIP is a phase 3b open-label, active comparator, randomized clinical trial designed to assess the efficacy and safety of IPX203 in patients with advanced PD and motor fluctuations. The study aims to compare IPX203 with standard immediate-release levodopa-carbidopa, focusing on improving ON time and reducing OFF time through personalized dosing schedules. Unlike previous trials, ADIP allows dosing intervals tailored to individual patient needs. This flexible approach is expected to enhance symptom control and overall patient outcomes. The trial will run for up to 25 weeks, including a 1-week screening, 12-week treatment, and an optional 12-week extension. It will enroll 92 patients across sites in Italy, Spain, and Poland.

At Zambon Biotech we are fully committed to build a long-term pipeline of innovative medicines that make patients’ lives better. Given our group’s capabilities in commercialization and our existing footprint in neurology, particularly Parkinson’s, we believe IPX203 could represent a valuable therapeutic option in Europe to improve the lives of moderate to severe Parkinson patients” said Frank Weber, M.D, Chief Executive Officer at Zambon Biotech.

About Zambon Biotech SA

Zambon Biotech SA is a specialized biotech company that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules. Zambon Biotech is part of Zambon, a modern multinational chemical-pharmaceutical company established in 1906 in Vicenza, whose history is founded on the values of an Italian family committed to innovating cure and care to improve patients’ lives. Zambon employs 2,768 people worldwide, is present in 23 countries in Europe, America and Asia, and has production facilities in Italy, Switzerland, China, Brazil and in France with its APIs and CDMO site. Thanks to its innovative, quality products commercialized in 87 countries, the group reported a revenue of 885 million euros in 2024. Alongside the three historical therapeutic areas – diseases of the respiratory system, urinary tract infections and pain treatment – Zambon pharma business is focused on developing treatments for neurodegenerative diseases such as Parkinson’s or rare diseases such as cystic fibrosis, BOS, to which is linked the major 2019 acquisition of Breath Therapeutics, and NCFB. For further information on Zambon please visit www.zambon.com

1 https://www.who.int/publications/i/item/9789240050983

Contacts

Marco Allegrini, Corporate Communications
media@zambongroup.com

Market Opportunity
Particl Logo
Particl Price(PART)
$0.3178
$0.3178$0.3178
+0.95%
USD
Particl (PART) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

U.S. Coinbase Premium Turns Negative Amid Asian Buying Surge

U.S. Coinbase Premium Turns Negative Amid Asian Buying Surge

U.S. institutional demand falls as Asian markets buy Bitcoin dips, causing negative Coinbase premium.
Share
CoinLive2025/12/23 14:20
Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security

Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security

BitcoinWorld Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security Ever wondered why withdrawing your staked Ethereum (ETH) isn’t an instant process? It’s a question that often sparks debate within the crypto community. Ethereum founder Vitalik Buterin recently stepped forward to defend the network’s approximately 45-day ETH unstaking period, asserting its crucial role in safeguarding the network’s integrity. This lengthy waiting time, while sometimes seen as an inconvenience, is a deliberate design choice with profound implications for security. Why is the ETH Unstaking Period a Vital Security Measure? Vitalik Buterin’s defense comes amidst comparisons to other networks, like Solana, which boast significantly shorter unstaking times. He drew a compelling parallel to military operations, explaining that an army cannot function effectively if its soldiers can simply abandon their posts at a moment’s notice. Similarly, a blockchain network requires a stable and committed validator set to maintain its security. The current ETH unstaking period isn’t merely an arbitrary delay. It acts as a critical buffer, providing the network with sufficient time to detect and respond to potential malicious activities. If validators could instantly exit, it would open doors for sophisticated attacks, jeopardizing the entire system. Currently, Ethereum boasts over one million active validators, collectively staking approximately 35.6 million ETH, representing about 30% of the total supply. This massive commitment underpins the network’s robust security model, and the unstaking period helps preserve this stability. Network Security: Ethereum’s Paramount Concern A shorter ETH unstaking period might seem appealing for liquidity, but it introduces significant risks. Imagine a scenario where a large number of validators, potentially colluding, could quickly withdraw their stake after committing a malicious act. Without a substantial delay, the network would have limited time to penalize them or mitigate the damage. This “exit queue” mechanism is designed to prevent sudden validator exodus, which could lead to: Reduced decentralization: A rapid drop in active validators could concentrate power among fewer participants. Increased vulnerability to attacks: A smaller, less stable validator set is easier to compromise. Network instability: Frequent and unpredictable changes in validator numbers can lead to performance issues and consensus failures. Therefore, the extended period is not a bug; it’s a feature. It’s a calculated trade-off between immediate liquidity for stakers and the foundational security of the entire Ethereum ecosystem. Ethereum vs. Solana: Different Approaches to Unstaking When discussing the ETH unstaking period, many point to networks like Solana, which offers a much quicker two-day unstaking process. While this might seem like an advantage for stakers seeking rapid access to their funds, it reflects fundamental differences in network architecture and security philosophies. Solana’s design prioritizes speed and immediate liquidity, often relying on different consensus mechanisms and validator economics to manage security risks. Ethereum, on the other hand, with its proof-of-stake evolution from proof-of-work, has adopted a more cautious approach to ensure its transition and long-term stability are uncompromised. Each network makes design choices based on its unique goals and threat models. Ethereum’s substantial value and its role as a foundational layer for countless dApps necessitate an extremely robust security posture, making the current unstaking duration a deliberate and necessary component. What Does the ETH Unstaking Period Mean for Stakers? For individuals and institutions staking ETH, understanding the ETH unstaking period is crucial for managing expectations and investment strategies. It means that while staking offers attractive rewards, it also comes with a commitment to the network’s long-term health. Here are key considerations for stakers: Liquidity Planning: Stakers should view their staked ETH as a longer-term commitment, not immediately liquid capital. Risk Management: The delay inherently reduces the ability to react quickly to market volatility with staked assets. Network Contribution: By participating, stakers contribute directly to the security and decentralization of Ethereum, reinforcing its value proposition. While the current waiting period may not be “optimal” in every sense, as Buterin acknowledged, simply shortening it without addressing the underlying security implications would be a dangerous gamble for the network’s reliability. In conclusion, Vitalik Buterin’s defense of the lengthy ETH unstaking period underscores a fundamental principle: network security cannot be compromised for the sake of convenience. It is a vital mechanism that protects Ethereum’s integrity, ensuring its stability and trustworthiness as a leading blockchain platform. This deliberate design choice, while requiring patience from stakers, ultimately fortifies the entire ecosystem against potential threats, paving the way for a more secure and reliable decentralized future. Frequently Asked Questions (FAQs) Q1: What is the main reason for Ethereum’s long unstaking period? A1: The primary reason is network security. A lengthy ETH unstaking period prevents malicious actors from quickly withdrawing their stake after an attack, giving the network time to detect and penalize them, thus maintaining stability and integrity. Q2: How long is the current ETH unstaking period? A2: The current ETH unstaking period is approximately 45 days. This duration can fluctuate based on network conditions and the number of validators in the exit queue. Q3: How does Ethereum’s unstaking period compare to other blockchains? A3: Ethereum’s unstaking period is notably longer than some other networks, such as Solana, which has a two-day period. This difference reflects varying network architectures and security priorities. Q4: Does the unstaking period affect ETH stakers? A4: Yes, it means stakers need to plan their liquidity carefully, as their staked ETH is not immediately accessible. It encourages a longer-term commitment to the network, aligning staker interests with Ethereum’s stability. Q5: Could the ETH unstaking period be shortened in the future? A5: While Vitalik Buterin acknowledged the current period might not be “optimal,” any significant shortening would likely require extensive research and network upgrades to ensure security isn’t compromised. For now, the focus remains on maintaining robust network defenses. Found this article insightful? Share it with your friends and fellow crypto enthusiasts on social media to spread awareness about the critical role of the ETH unstaking period in Ethereum’s security! To learn more about the latest Ethereum trends, explore our article on key developments shaping Ethereum’s institutional adoption. This post Crucial ETH Unstaking Period: Vitalik Buterin’s Unwavering Defense for Network Security first appeared on BitcoinWorld.
Share
Coinstats2025/09/18 15:30
USD/JPY jumps to near 148.30 as Fed Powell’s caution on rate cuts boosts US Dollar

USD/JPY jumps to near 148.30 as Fed Powell’s caution on rate cuts boosts US Dollar

The post USD/JPY jumps to near 148.30 as Fed Powell’s caution on rate cuts boosts US Dollar appeared on BitcoinEthereumNews.com. USD/JPY climbs to near 148.30 as Fed’s Powell didn’t endorse aggressive dovish stance. Fed’s Powell warns of slowing job demand and upside inflation risks. Japan’s Jibun Bank Manufacturing PMI declines at a faster pace in September. The USD/JPY pair trades 0.45% higher to near 148.30 during the European trading session on Wednesday. The pair gains sharply as the US Dollar (USD) outperforms a majority of its peers, following comments from Federal Reserve (Fed) Chair Jerome Powell that the central bank needs to be cautious on further interest rate cuts. During the press time, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, rises almost 0.4% to near 97.60. The USD Index resumes its upside journey after a two-day corrective move. On Tuesday, Fed’s Powell stated at the Greater Providence Chamber of Commerce that the upside inflation risks and labor market concerns have posed a challenging situation for the central bank, which is prompting officials to exercise caution on further monetary policy easing. Powell also stated that the current interest rate range is “well positioned to respond to potential economic developments”. Fed Powell’s comments were similar to statements from Federal Open Market Committee (FOMC) members St. Louis Fed President Alberto Musalem, Atlanta Fed President Raphael Bostic, and Cleveland Fed President Beth Hammack who stated on Monday that the central bank needs to cautious over unwinding monetary policy restrictiveness further, citing persistent inflation risks. Going forward, investors will focus on the US Durable Goods Orders and Personal Consumption Expenditure Price Index (PCE) data for August, which will be released on Thursday and Friday, respectively. In Japan, the manufacturing business activity has declined again in September. Preliminary Jibun Bank Manufacturing PMI data came in lower at 48.4 against 49.7 in August. Economists had anticipated the Manufacturing PMI to…
Share
BitcoinEthereumNews2025/09/25 01:31